Alzheimer’s Blood Diagnostics: What Siemens’ Bio-Hermes-002 Role Means for IVD

Blood-based diagnostics are becoming one of the most important directions in Alzheimer’s disease research. Compared with traditional approaches that often rely on imaging or cerebrospinal fluid testing, blood biomarker testing may offer a more accessible way to support earlier screening, research, and clinical pathway development.

In 2026, Siemens Healthineers joined the Bio-Hermes-002 study led by the Global Alzheimer’s Platform Foundation. The study focuses on blood-based and digital biomarkers that may help improve the prediction, detection, and diagnosis of Alzheimer’s disease and related dementias.

For the IVD industry, this development is not only a neuroscience milestone. It also reflects a broader trend: high-value diagnostics are moving toward biomarker-based testing, scalable assay platforms, and more standardized production workflows.

1. Why Alzheimer’s Blood Diagnostics Are Gaining Attention

Alzheimer’s disease is closely associated with biological changes such as amyloid and tau pathology. In recent years, blood-based biomarkers have gained strong attention because they may provide useful information through a simple blood draw, reducing the burden of more invasive or expensive testing methods.

Biomarkers such as phosphorylated tau 217, often written as pTau217 or p-tau217, have become important research targets. These markers are being evaluated for their potential to support earlier detection, patient stratification, treatment research, and long-term disease monitoring.

2. What Is Bio-Hermes-002?

Bio-Hermes-002 is a collaborative research study designed to evaluate blood-based biomarkers, digital biomarkers, and imaging-related data across a wide range of cognitive conditions. Its goal is to generate evidence that may improve how Alzheimer’s disease and related dementias are predicted, detected, and diagnosed.

By joining the study as a licensed partner, Siemens Healthineers adds diagnostic technology expertise to a global effort that already involves multiple pharmaceutical, diagnostics, biomarker, and research organizations. This type of collaboration is important because Alzheimer’s diagnostics requires evidence from different technologies, populations, and testing environments.

3. Why pTau217 Matters in Blood-Based Testing

Phosphorylated tau 217 is one of the most discussed blood biomarkers in Alzheimer’s research. It is associated with tau pathology and has been studied for its potential value in identifying Alzheimer’s disease-related changes.

Siemens Healthineers has also expanded its brain health research portfolio with Atellica IM pTau217 and BDTau research assays. This reflects a larger direction in diagnostics: biomarker testing needs not only good antibody design, but also reliable assay platforms, stable reagent systems, and repeatable workflow control.

4. What This Means for the IVD Industry

The Siemens Healthineers and Bio-Hermes-002 collaboration shows how modern diagnostics are moving toward earlier, more accessible, and more data-driven testing. For IVD manufacturers, this trend creates higher expectations for assay sensitivity, reagent stability, material compatibility, and production repeatability.

Whether a test is built for a central laboratory platform, a POCT device, or a rapid test format, the same principle applies: reliable diagnostic performance depends on both biological design and manufacturing control.

• Sensitive biomarkers require stable reagent preparation and controlled dispensing.
• Assay consistency depends on material quality, process validation, and batch-to-batch control.
• Scalable diagnostics require equipment that can support repeatable production workflows.
• Earlier screening trends may increase demand for accessible and manufacturable test formats.

5. From Biomarker Discovery to Manufacturable Diagnostics

A promising biomarker does not automatically become a reliable diagnostic product. Between discovery and market-ready testing, manufacturers must evaluate antibody performance, reagent formulation, sample matrix effects, stability, signal readout, production equipment, and quality control.

For lateral flow tests and other POCT formats, production processes such as reagent dispensing, membrane selection, lamination, cutting, assembly, and packaging can affect final product consistency. This is why early process design is important even during R&D and pilot production.

6. Why Production Control Matters for POCT and Rapid Test Formats

In POCT and rapid test manufacturing, small process variations can lead to visible differences in signal intensity, flow behavior, reaction time, or product appearance. This becomes even more important when the test targets low-abundance biomarkers or requires high sensitivity.

Equipment such as dispenser and spraying machines, lamination systems, cutters, assembly machines, and packaging systems helps manufacturers improve workflow stability. At the same time, suitable POCT raw materials are essential for consistent absorption, flow, binding, and production compatibility.

7. How Veldi Supports IVD Manufacturing Workflows

Veldi provides rapid test production equipment, POCT automation equipment, selected raw materials, and customized manufacturing support for IVD projects. Our solutions cover key workflow steps such as dispensing, lamination, cutting, cassette assembly, pouching, labeling, and coding.

As biomarker-based diagnostics continue to develop, manufacturers need practical production systems that can support R&D evaluation, pilot production, and scale-up manufacturing. Veldi helps customers evaluate suitable equipment configurations and material options according to product structure, process requirements, and capacity targets.

FAQ

1. What are Alzheimer’s blood diagnostics?

Alzheimer’s blood diagnostics refer to tests that measure blood-based biomarkers associated with Alzheimer’s disease pathology. These tests are being studied to support earlier detection, patient evaluation, and disease monitoring.

2. Why is pTau217 important?

pTau217 is a phosphorylated tau biomarker that has received strong research attention because of its association with Alzheimer’s disease-related changes. It is being evaluated in blood-based testing approaches.

3. What does this trend mean for IVD manufacturers?

It means manufacturers may need stronger capabilities in sensitive assay development, reagent stability, material selection, process validation, automation, and production consistency.

4. Are blood biomarker tests the same as rapid tests?

Not necessarily. Blood biomarker tests may be developed for central laboratory platforms, research assays, POCT systems, or other formats. However, all formats require reliable assay design and controlled manufacturing workflows.

Conclusion